Bayer cuts 227 jobs at Jivi plant in California

By Flora Southey contact

- Last updated on GMT

(Image: Getty/jarun011)
(Image: Getty/jarun011)

Related tags: Bayer, California

Having now secured regulatory approval for all three of its haemophilia A therapies made in Berkeley, Bayer is implementing “organisational changes” across the facility.

Last month, Bayer received regulatory approval for haemophilia A treatment, Jivi, in the US and Japan.

Haemophilia A is a genetic disorder caused by a missing or defective clotting protein, factor VIII.

Jivi is classified as a recombinant factor VIII (rFVIII) product and joins Bayer’s two rFVIII treatments already on the market – Kogenate and Kovaltry. Bayer manufactures all three treatments at the Californian facility.

Earlier this week, Bayer announced its regulatory success in the haemophilia field had prompted an internal restructure, which will see headcount in Berkely reduced by 227.

“Our transition into commercial production with three products has resulted in the need for organisational changes to enable these efficiencies,” ​a spokesperson told us in an emailed statement.

“The decision will not impact product availability as we remain committed to providing a portfolio of treatment options to serve the individual needs of the haemophilia community,” ​the spokesperson added.

In other restructuring news, earlier this year Bayer announced plans​ to transfer technology from a facility in Ansung, South Korea, to Berlin, and divested its prescription dermatology unit​ to Danish firm, LEO Pharma.

Related news

Related products

Featured eBook: Complex Protein Production

Featured eBook: Complex Protein Production

Catalent Pharma Solutions | 06-Mar-2018 | Technical / White Paper

Download the eBook written by Catalent experts to learn about innovative products and techniques for scale-up of complex biologics, get optimal cell culture...

Related suppliers

Follow us

Products

View more

Webinars